Abstract
Computational methodologies are used to increase the efficiency of drug discovery process by rendering the design of new drug candidates more rapid and cost-efficient. In silico techniques can be divided in two main groups. Structure-based drug design procedures can be applied (such as docking simulations) if the target is known from experimental (i.e., X-ray crystallographic studies, NMR studies) or theoretical sources (receptor structure built by homology modeling techniques). Otherwise, ligand-based drug design methods can be used (e.g., QSAR or 3D QSAR models, pharmacophoric models) based on the analysis of a number of ligands known to act with a common mechanism of action. Adenosine receptors (ARs) are a family of G-protein coupled receptors (GPCRs) of great interest as targets for therapeutic intervention. Due partly to the lack of reliable adenosine receptor structures, ligand-based drug discovery methods remain the major computational molecular modeling approach applied in the research of new AR ligands. The scope of this review is to summarize the results on pharmacophoric models and 3D QSAR studies concerning AR ligands. In particular, the review will focus on the use of such ligand-based computational techniques for the identification of new AR ligands and/or for their optimization.
Keywords: Pharmacophore, 3D QSAR, CoMFA, adenosine receptors
Current Topics in Medicinal Chemistry
Title: Pharmacophoric Models and 3D QSAR Studies of the Adenosine Receptor Ligands
Volume: 10 Issue: 10
Author(s): C. Tintori, F. Manetti and M. Botta
Affiliation:
Keywords: Pharmacophore, 3D QSAR, CoMFA, adenosine receptors
Abstract: Computational methodologies are used to increase the efficiency of drug discovery process by rendering the design of new drug candidates more rapid and cost-efficient. In silico techniques can be divided in two main groups. Structure-based drug design procedures can be applied (such as docking simulations) if the target is known from experimental (i.e., X-ray crystallographic studies, NMR studies) or theoretical sources (receptor structure built by homology modeling techniques). Otherwise, ligand-based drug design methods can be used (e.g., QSAR or 3D QSAR models, pharmacophoric models) based on the analysis of a number of ligands known to act with a common mechanism of action. Adenosine receptors (ARs) are a family of G-protein coupled receptors (GPCRs) of great interest as targets for therapeutic intervention. Due partly to the lack of reliable adenosine receptor structures, ligand-based drug discovery methods remain the major computational molecular modeling approach applied in the research of new AR ligands. The scope of this review is to summarize the results on pharmacophoric models and 3D QSAR studies concerning AR ligands. In particular, the review will focus on the use of such ligand-based computational techniques for the identification of new AR ligands and/or for their optimization.
Export Options
About this article
Cite this article as:
Tintori C., Manetti F. and Botta M., Pharmacophoric Models and 3D QSAR Studies of the Adenosine Receptor Ligands, Current Topics in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/156802610791293118
DOI https://dx.doi.org/10.2174/156802610791293118 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diuretics in the Treatment of Elderly Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural Products in Drug Discovery - Concepts and Approaches for Tracking Bioactivity
Current Organic Chemistry Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Current Drug Targets microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art
Current Drug Metabolism Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Editorial: Targeting Neuregulin1 and HER Receptor Tyrosine Kinases for Therapy of Breast Cancer and Heart Failure
Current Pharmaceutical Design Management of Cardiovascular Risk Factors in Patients with Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Copeptin in Preeclampsia Development
Current Women`s Health Reviews Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry